Primary outcome
| Parameter . | Chemotherapy only, n (%) . | Chemotherapy + lestaurtinib, n (%) . | P . |
|---|---|---|---|
| No. of total patients | 112 | 112 | > .99 |
| CR | 13 (12) | 19 (17) | .25 |
| CRp | 10 (9) | 10 (9) | > .99 |
| Total CR/CRp | 23 (21) | 29 (26) | .35 |
| First remission 1-6 mo, CR/CRp | 6 (11) | 10 (19) | .42 |
| First remission ≥ 6 mo, CR/CRp | 17 (29) | 19 (32) | .84 |
| < 50 y of age, CR/CRp | 4 (12) | 9 (27) | .21 |
| ≥ 50 y of age, CR/CRp | 19 (24) | 20 (25) | > .99 |
| Parameter . | Chemotherapy only, n (%) . | Chemotherapy + lestaurtinib, n (%) . | P . |
|---|---|---|---|
| No. of total patients | 112 | 112 | > .99 |
| CR | 13 (12) | 19 (17) | .25 |
| CRp | 10 (9) | 10 (9) | > .99 |
| Total CR/CRp | 23 (21) | 29 (26) | .35 |
| First remission 1-6 mo, CR/CRp | 6 (11) | 10 (19) | .42 |
| First remission ≥ 6 mo, CR/CRp | 17 (29) | 19 (32) | .84 |
| < 50 y of age, CR/CRp | 4 (12) | 9 (27) | .21 |
| ≥ 50 y of age, CR/CRp | 19 (24) | 20 (25) | > .99 |